Acupotomy for knee osteoarthritis: a randomized controlled trial

注册号:

Registration number:

ITMCTR2100004372

最近更新日期:

Date of Last Refreshed on:

2021-02-04

注册时间:

Date of Registration:

2021-02-04

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刀治疗膝骨关节炎的随机对照临床试验

Public title:

Acupotomy for knee osteoarthritis: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刀治疗膝骨关节炎的随机对照临床试验

Scientific title:

Acupotomy for knee osteoarthritis: a randomized controlled trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100043005 ; ChiMCTR2100004372

申请注册联系人:

李树明

研究负责人:

李树明

Applicant:

Shu-Ming Li

Study leader:

Shu-Ming Li

申请注册联系人电话:

Applicant telephone:

+86 010-52176050

研究负责人电话:

Study leader's telephone:

+86 010-52176050

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lishuming@bjzhongyi.com

研究负责人电子邮件:

Study leader's E-mail:

lishuming@bjzhongyi.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区美术馆后街23号

研究负责人通讯地址:

北京市东城区美术馆后街23号

Applicant address:

23 Meishuguan Back Street, Dongcheng District, Beijing, China

Study leader's address:

23 Meishuguan Back Street, Dongcheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京中医医院

Applicant's institution:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020BL02-057-02

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

首都医科大学附属北京中医医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021/1/29 0:00:00

伦理委员会联系人:

刘声

Contact Name of the ethic committee:

Sheng Liu

伦理委员会联系地址:

北京市东城区美术馆后街23号

Contact Address of the ethic committee:

23 Meishuguan Back Street, Dongcheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京中医医院

Primary sponsor:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

研究实施负责(组长)单位地址:

北京市东城区美术馆后街23号

Primary sponsor's address:

23 Meishuguan Back Street, Dongcheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京中医医院

具体地址:

北京市东城区美术馆后街23号

Institution
hospital:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Address:

23 Meishuguan Back Street, Dongcheng District, Beijing

经费或物资来源:

首都卫生发展科研专项项目

Source(s) of funding:

Capital's Funds for Health Improvement and Research

研究疾病:

膝骨关节炎

研究疾病代码:

Target disease:

Knee Osteoarthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

评价针刀治疗膝骨关节炎的有效性及安全性

Objectives of Study:

To evaluate the effect and safety of acupotomy for knee osteoarthritis

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合美国风湿病学会关于膝骨关节炎的诊断标准; (2)K-L分级2-4级; (3)NRS疼痛评分≥4; (4)年龄40-80岁; (5)病程大于6个月; (5)签署知情同意书。

Inclusion criteria

(1) Meet the diagnosis of knee osteoarthritis according to the American College of Rheumatology (ACR) criteria; (2) Kellgren–Lawrence grading from II to IV; (3) Knee pain score >=4 on an 11-point numerical rating scale (NRS); (4) Aged 40 to 80 years old; (5) Symptomtoms have been present for more than 6 months; (5) Signing the informed consent.

排除标准:

(1)既往膝关节手术史,或准备接受膝关节手术; (2)自身免疫疾病、感染、肿瘤、创伤、骨折等因素导致膝关节病变者; (3)凝血功能异常; (4)外用双氯芬酸二乙胺乳胶剂药物过敏者; (5)合并有严重身体和心理疾病者; (6)怀孕或哺乳期女性; (7)过去3个月内接受过其它相关治疗如针刀、针灸和膝关节腔注射; (8)金属过敏或恐惧怕针刀者; (9)近3个月内参加其它临床研究者。

Exclusion criteria:

(1) History of knee surgery or waiting for surgery (knee replacement or knee arthroscopy); (2) Knee joint lesions caused by autoimmune diseases,infections,tumors,trauma,fracture and other factors; (3) Abnormal coagulation function; (4) Allergy to topical diclofenac diethylamine latex; (5) Severe organic or mental diseases; (6) Pregnant and lactating women; (7) History of receiving other related treatment within the past 3 months, such as acupotomy,acupuncture and intraarticular injection; (8) Metal allergy or fear of acupotomology; (9) Participated in other clinical trials within the last 3 months.

研究实施时间:

Study execute time:

From 2021-03-01

To      2023-06-30

征募观察对象时间:

Recruiting time:

From 2021-03-01

To      2022-06-30

干预措施:

Interventions:

组别:

针刀组

样本量:

100

Group:

acupotomy group

Sample size:

干预措施:

针刀联合外用双氯芬酸二乙胺乳胶剂

干预措施代码:

Intervention:

acupotomy and topical diclofenac

Intervention code:

组别:

双氯芬酸组

样本量:

100

Group:

diclofenac group

Sample size:

干预措施:

外用双氯芬酸二乙胺乳胶剂

干预措施代码:

Intervention:

topical diclofenac

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京中医医院

单位级别:

三级甲等

Institution/hospital:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

有效应答率

指标类型:

主要指标

Outcome:

response rate

Type:

Primary indicator

测量时间点:

第4周

测量方法:

Measure time point of outcome:

week 4

Measure method:

指标中文名:

WOMAC僵硬亚量表

指标类型:

次要指标

Outcome:

WOMAC stiffness subcale

Type:

Secondary indicator

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

指标中文名:

血清和关节液炎症因子含量

指标类型:

附加指标

Outcome:

inflammatory cytokine levels in serum and joint fluid

Type:

Additional indicator

测量时间点:

第0周、第4周

测量方法:

Measure time point of outcome:

Week 0, Week 4

Measure method:

指标中文名:

WOMAC功能亚量表

指标类型:

次要指标

Outcome:

WOMAC functional subscale

Type:

Secondary indicator

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

指标中文名:

WOMAC疼痛亚量表

指标类型:

次要指标

Outcome:

WOMAC pain subscale

Type:

Secondary indicator

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

quality of life (SF-12)

Type:

Secondary indicator

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

指标中文名:

应急药物使用情况

指标类型:

次要指标

Outcome:

Use of rescue medication

Type:

Secondary indicator

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

指标中文名:

NRS评分

指标类型:

次要指标

Outcome:

NRS score

Type:

Secondary indicator

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

指标中文名:

不良事件

指标类型:

副作用指标

Outcome:

adverse events

Type:

Adverse events

测量时间点:

第0周、第4周、第8周、第24周

测量方法:

Measure time point of outcome:

Weeks 0, 4, 8, and 24

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

滑液

组织:

膝关节

Sample Name:

synovial fluid

Tissue:

knee joint

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本试验采用区组随机方法,独立的研究者使用SPSS20.0软件产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Block randomization will be adopted in this trial. An independent researcher will use SPSS 20.0 software to generate randomization sequence.

盲法:

由于针刀治疗的特殊性,治疗过程中无法对针刀医生及受试者实施盲法。对评价者和统计分析人员设盲。

Blinding:

Because of the particularity of acupotomy therapy, acupotomy doctors and patients cannot be blinded during the treatment. The outcome assessors and statisticians will be blinded to group allocation.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

使用临床试验公共管理平台ResMan(www.medresman.org)共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data will be shared using Resman (www.medresman.org) (a public clinical trial management platform).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过纸质CRF表记录元数据,再将数据录入到电子数据采集系统。数据管理由专人负责。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The metadata will be recorded through a CRF form, and then input into electronic data caputure system. The data management will be handled by an independent person.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above